FrancophonIA/ELRC3.0 huggingface dataset:
English: Uncommon cases of jaundice (yellowing of the skin and/or whites of the eyes) have also been reported.
Croatian: Prijavljeni su i manje česti slučajevi žutice (žuta boja kože i/ili bjeloočnica).
English: Furthermore, irbesartan induced hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at ≥ 90 mg/kg/day, in macaques at ≥ 10 mg/kg/day).
Croatian: Nadalje, irbesartan je izazivao hiperplaziju/hipertrofiju jukstaglomerularnih stanica (u štakora pri dozi od ≥ 90 mg/kg/dan, u makaki majmuna pri dozi od ≥ 10 mg/kg/dan).
English: As is the case with other medicinal products that affect the renin-angiotensin system, black hypertensive patients have notably less response to irbesartan monotherapy.
Croatian: Kao što je to slučaj s ostalim lijekovima koji utječu na renin-angiotenzinski sustav, hipertenzivni bolesnici crne rase slabije reagiraju na monoterapiju irbesartanom.
English: Non-steroidal anti-inflammatory drugs: when angiotensin II antagonists are administered simultaneously with non-steroidal anti-inflammatory drugs (i.e. selective COX-2 inhibitors, acetylsalicylic acid (> 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.
Croatian: Nesteroidni protuupalni lijekovi: kad se antagonisti angiotenzina II primjenjuju istodobno s nesteroidnim protuupalnim lijekovima (tj. selektivnim inhibitorima COX-2, acetilsalicilatnom kiselinom (> 3 g/dan) i neselektivnim NSAIL) moguć je oslabljeni antihipertenzivni učinak.
English: Side effects reported in clinical studies for patients treated with Aprovel were: Very common (may affect more than 1 in 10 people): if you suffer from high blood pressure and type 2 diabetes with kidney disease, blood tests may show an increased level of potassium.
Croatian: U kliničkim ispitivanjima s bolesnicima liječenima lijekom Aprovel prijavljene su sljedeće nuspojave: Vrlo često (mogu se javiti u više od 1 na 10 osoba): ako imate povišen krvni tlak i šećernu bolest tipa 2 te bolest bubrega, krvne pretrage mogu pokazati povišene vrijednosti kalija.
English: sanofi-aventis groupe 54, rue La Boétie F-75008 Paris - France
Croatian: sanofi-aventis groupe 54, rue La Boétie F-75008 Pariz - Francuska
English: In patients with high blood pressure and type 2 diabetes with kidney disease, dizziness when getting up from a lying or sitting position, low blood pressure when getting up from a lying or sitting position, pain in joints or muscles and decreased levels of a protein in the red blood cells (haemoglobin) were also reported.
Croatian: U bolesnika s povišenim krvnim tlakom, šećernom bolešću tipa 2 i bubrežnom bolešću također su prijavljeni omaglica i nizak krvni tlak nakon ustajanja iz sjedećeg ili ležećeg položaja, bol u zglobovima ili mišićima i smanjene razine proteina u crvenim krvnim stanicama (hemoglobina).
English: Terms marked with a star (*) refer to the adverse reactions that were additionally reported in > 2% of diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria and in excess of placebo.
Croatian: Pojmovi označeni zvjezdicom (*) odnose se na nuspojave koje su dodatno prijavljene u više od 2% dijabetičkih hipertenzivnih bolesnika s kroničnom insuficijencijom bubrega i manifestnom proteinurijom i to češće nego kod placeba.
English: Irbesartan does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also degrades bradykinin into inactive metabolites.
Croatian: Irbesartan ne inhibira ACE (kininazu II), enzim koji stvara angiotenzin-II te degradira bradikinin u neaktivne metabolite.
English:  If you have any further questions, ask your doctor or pharmacist.
Croatian: Ako imate dodatnih pitanja, obratite se svom liječniku ili ljekarniku.
English: No significant pharmacokinetic or pharmacodynamic interactions were observed when irbesartan was coadministered with warfarin, a medicinal product metabolised by CYP2C9.
Croatian: Nisu zabilježene značajne farmakokinetičke ni farmakodinamičke interakcije kod istodobne primjene irbesartana i varfarina, lijeka koji se metabolizira pomoću CYP2C9.
English: Additional antihypertensive agents (excluding ACE inhibitors, angiotensin II receptor antagonists and dihydropyridine calcium blockers) were added as needed to help achieve the blood pressure goal.
Croatian: Dodatni antihipertenzivi (isključujući ACE inhibitore, antagoniste receptora angiotenzina II i dihidropiridinske blokatore kalcijevih kanala) dodavani su prema potrebi kako bi se postigao ciljni krvni tlak.
English: A limited accumulation of irbesartan (18%) in plasma was observed upon repeated once daily dosing.
Croatian: Ograničeno nakupljanje irbesartana u plazmi (18%) opaženo je nakon ponovljenog doziranja jedanput dnevno.
English: Approximately 33% of patients in the irbesartan group reached the primary renal composite endpoint compared to 39% and 41% in the placebo and amlodipine groups [20% relative risk reduction versus placebo (p = 0.024) and 23% relative risk reduction compared to amlodipine (p = 0.006)].
Croatian: Približno 33% bolesnika u irbesartan skupini dostiglo je primarnu složenu mjeru ishoda ispitivanja za bubrežnu bolest, u usporedbi sa 39% u placebo i 41% u amlodipin skupini [smanjenje relativnog rizika za 20% u odnosu na placebo (p=0,024) i smanjenje relativnog rizika za 23% u usporedbi s amplodipinom (p=0,006)].
English: IRMA 2 was a placebo-controlled double blind morbidity study in 590 patients with type 2 diabetes, microalbuminuria (30-300 mg/day) and normal renal function (serum creatinine ≤ 1.5 mg/dl in males and < 1.1 mg/dl in females).
Croatian: IRMA 2 bilo je placebom kontrolirano, dvostruko slijepo ispitivanje morbiditeta u 590 bolesnika sa šećernom bolešću tipa 2, mikroalbuminurijom (30-300 mg/dan) i normalnom bubrežnom funkcijom (serumski kreatinin ≤ 1,5 mg/dl u muškaraca i < 1,1 mg/dl u žena).
English: Intravascular volume depletion: symptomatic hypotension, especially after the first dose, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting.
Croatian: Smanjenje intravaskularnog volumena: simptomatska hipotenzija, posebice nakon prve doze, može se pojaviti u bolesnika sa hipovolemijom i/ili hiponatrijemijom zbog snažne diuretske terapije, restrikcijske dijete sa smanjenim unosom soli, proljeva ili povraćanja.
English: Do not use this medicine after the expiry date which is stated on the carton and on the blister after EXP.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i blisteru iza oznake “EXP“.
English: PHARMACEUTICAL FORM AND CONTENTS 14 tablets 28 tablets 56 tablets 56 x 1 tablets 98 tablets METHOD AND ROUTE(S) OF ADMINISTRATION Oral use.
Croatian: OBLIK I SADRŽAJ 14 tableta 28 tableta 56 tableta 56 x 1 tableta 98 tableta NAČIN I PUT(EVI) PRIMJENE LIJEKA Primjena kroz usta.
English: Patients in all treatment groups typically received between 2 and 4 antihypertensive agents (e.g., diuretics, beta blockers, alpha blockers) to reach a predefined blood pressure goal of ≤ 135/85 mmHg or a 10 mmHg reduction in systolic pressure if baseline was > 160 mmHg.
Croatian: Bolesnici u svim liječenim skupinama obično su uzimali između 2 i 4 antihipertenzivna lijeka (npr. diuretike, beta blokatore, alfa blokatore) kako bi postigli unaprijed definirani krvni tlak od ≤ 135/85 mmHg ili smanjenje sistoličkog tlaka za 10 mmHg ako je početna vrijednost bila > 160 mmHg.
English: Peak plasma concentrations are attained at 1.5-2 hours after oral administration.
Croatian: Vršne koncentracije u plazmi postižu se 1,5 do 2 sata nakon peroralne primjene.
English: Discontinuation due to any clinical or laboratory adverse event was less frequent for irbesartan-treated patients (3.3%) than for placebo-treated patients (4.5%).
Croatian: Prekid terapije zbog određenih kliničkih ili laboratorijskih štetnih događaja bio je manje čest u bolesnika liječenih irbesartanom (3,3%) nego u skupini bolesnika koji su primali placebo (4,5%).
English: Hypertensive patients with type 2 diabetes and renal disease: the effects of irbesartan both on renal and cardiovascular events were not uniform across all subgroups, in an analysis carried out in the study with patients with advanced renal disease.
Croatian: Hipertenzivni bolesnici sa šećernom bolešću tipa 2 i bubrežnom bolešću: učinak irbesartana na događaje povezane s bubrezima i kardiovaskularnim sustavom nije bio ujednačen u svim podskupinama u analizi rezultata ispitivanja bolesnika s uznapredovalom bubrežnom bolešću.
English: Hypertension and type 2 diabetes with renal disease
Croatian: Hipertenzija i šećerna bolest tipa 2 s bubrežnom bolešću
English: significant increases in plasma creatine kinase were commonly observed (1.7%) in irbesartan treated subjects.
Croatian: zabilježen je značajan porast kreatin kinaze u plazmi (1,7%) u bolesnika koji su uzimali irbesartan.
English: Suggested measures include induction of emesis and/or gastric lavage.
Croatian: Predložene mjere uključuju izazivanje povraćanja i/ili lavažu želuca.
English: In placebo-controlled trials in patients with hypertension, the overall incidence of adverse events did not differ between the irbesartan (56.2%) and the placebo groups (56.5%).
Croatian: U placebom kontroliranim kliničkim ispitivanjima u kojima su sudjelovali bolesnici s hipertenzijom, ukupna incidencija štetnih događaja nije se razlikovala između skupine koja je uzimala irbesartan (56,2%) i placebo skupine (56,5%).
English: In this case your doctor may perform regular blood tests, especially for measuring blood potassium levels in case of poor kidney function if you are going to have an operation (surgery) or be given anaesthetics if you are taking any of the following medicines used to treat high blood pressure:
Croatian: U tom će Vam slučaju Vaš liječnik možda raditi redovite pretrage krvi, posebno određivanje koncentracije kalija u krvi u slučaju oslabljene funkcije bubrega ako trebate ići na bilo kakav kirurški zahvat ili trebate primiti anestetike ako uzimate bilo koji od lijekova navedenih u nastavku, koji se koriste za liječenje visokog krvnog tlaka:
English: The concomitant use of Aprovel with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (glomerular filtration rate (GFR) <60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Croatian: Istodobna primjena lijeka Aprovel s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
English: When irbesartan is administered concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg daily), the antihypertensive response in black patients approaches that of white patients.
Croatian: Kada se irbesartan daje istodobno s niskom dozom hidroklorotiazida (npr. 12,5 mg dnevno), antihipertenzivni odgovor u bolesnika crne rase sličan je onome u pripadnika bijele rase.
English: Animal studies with irbesartan showed transient toxic effects (increased renal pelvic cavitation, hydroureter or subcutaneous oedema) in rat foetuses, which were resolved after birth.
Croatian: Ispitivanja irbesartana na životinjama pokazala su prolazne toksične učinke (povećana kavitacija bubrežnog pelvisa, hidroureter ili supkutani edem) u fetusa štakora, koji su se povukli nakon okota.
English: Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.
Croatian: Bolesnike treba na primjeren način hidrirati te na početku primjene istodobne terapije treba kontrolirati bubrežnu funkciju, kao i periodički nakon toga.
English: None of these increases were associated with identifiable clinical musculoskeletal events.
Croatian: Niti jedan od tih slučajeva nije povezan s poremećajima mišićnokoštanog sustava koje je bilo moguće utvrditi.
English: The frequency of the side effects listed below is defined using the following convention: Very common: may affect more than 1 in 10 people Common: may affect up to 1 in 10 people
Croatian: Učestalost dolje navedenih nuspojava definirana je na sljedeći način: vrlo često: mogu se javiti u više od 1 na 10 osoba često: mogu se javiti u manje od 1 na 10 osoba manje često: mogu se javiti u manje od 1 na 100 osoba
English: The study of the “Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus (IRMA 2)” shows that irbesartan 300 mg delays progression to overt proteinuria in patients with microalbuminuria.
Croatian: Kliničko ispitivanje „Učinak irbesartana na mikroalbuminuriju u hipertenzivnih bolesnika sa šećernom bolešću tipa 2 (IRMA 2)“ pokazuje da 300 mg irbesartana odgađa progresiju do izražene proteinurije u bolesnika s mikroalbuminurijom.
English: Lithium: the combination of lithium and Aprovel is not recommended (see section 4.5).
Croatian: Litij: ne preporučuje se kombinacija litija i lijeka Aprovel (vidjeti dio 4.5).
English: o an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems.
Croatian: ACE inhibitor (primjerice enalapril, lisinopril, ramipril), osobito ako imate bubrežne tegobe povezane sa šećernom bolešću. aliskiren.
English: Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Croatian: U svakoj skupini učestalosti nuspojave su prikazane u padajućem nizu prema ozbiljnosti.
English: After either oral or IV administration of 14C irbesartan, about 20% of the radioactivity is recovered in the urine, and the remainder in the faeces.
Croatian: Nakon peroralne ili i.v. primjene 14C irbesartana, približno 20% radioaktivnosti pojavilo se u mokraći, a ostatak u stolici.
English: Irbesartan is metabolised by the liver via glucuronide conjugation and oxidation.
Croatian: Irbesartan se metabolizira u jetri glukuronidnom konjugacijom i oksidacijom.
English: It is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen (see sections 4.3, 4.4, 4.5 and 5.1).
Croatian: Također je indiciran za liječenje bubrežne bolesti u odraslih bolesnika s hipertenzijom i šećernom bolešću tipa 2 u sklopu antihipertenzivne terapije (vidjeti dijelove 4.3, 4.4, 4.5 i 5.1).
English: Adjusted mean change of trough seated diastolic blood pressure (SeDBP) was as follows: 3.8 mmHg (low dose), 3.2 mmHg (medium dose), 5.6 mmHg (high dose).
Croatian: Prilagođena srednja vrijednost promjene dijastoličkog krvnog tlaka u sjedećem položaju (SjDKT) u „najnižoj točki djelovanja“ bila je sljedeća: 3,8 mmHg (niska doza), 3,2 mmHg (srednja doza) i 5,6 mmHg (visoka doza).
English: Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy: as with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.
Croatian: Stenoza aortnog ili mitralnog zaliska, opstruktivna hipertrofična kardiomiopatija: kao što je to slučaj i s ostalim vazodilatatorima, poseban oprez indiciran je u bolesnika s aortnom ili mitralnom stenozom ili opstruktivnom hipertrofičnom kardiomiopatijom.
English: When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).
Croatian: Ako se utvrdi trudnoća, treba odmah prekinuti terapiju antagonistima receptora angiotenzina II te treba, ako je to primjereno, započeti s alternativnom terapijom (vidjeti dio 4.3 i 4.6).
English: Aprovel is used in adult patients to treat high blood pressure (essential hypertension) to protect the kidney in patients with high blood pressure, type 2 diabetes and laboratory evidence of impaired kidney function.
Croatian: Aprovel se primjenjuje u odraslih bolesnika za liječenje visokog krvnog tlaka (esencijalne hipertenzije) zaštitu bubrega u bolesnika sa šećernom bolešću tipa 2 koji imaju povišeni krvni tlak i laboratorijski dokazanu oslabljenu bubrežnu funkciju.
English: An increased incidence of non-fatal MI and stroke was seen in females in the irbesartan-based regimen versus the amlodipine-based regimen, while hospitalization due to heart failure was reduced in the overall population.
Croatian: Povećana incidencija nefatalnog infarkta miokarda i moždanog udara zabilježena je u žena iz skupine koja je primala irbesartan u odnosu na skupinu koja je primala amlodipin, dok je u sveukupnoj populaciji hospitalizacija zbog srčanog zatajenja bila smanjena.
English: Hyperkalaemia: as with other medicinal products that affect the renin-angiotensin-aldosterone system, hyperkalaemia may occur during the treatment with Aprovel, especially in the presence of renal impairment, overt proteinuria due to diabetic renal disease, and/or heart failure.
Croatian: Hiperkalijemija: kao i kod ostalih lijekova koji djeluju na renin-angiotenzin-aldosteronski sustav, tijekom liječenja lijekom Aprovel može se pojaviti hiperkalijemija, posebice ako je prisutna oštećena bubrežna funkcija, izražena proteinurija zbog dijabetičke bubrežne bolesti i/ili zatajenje srca.
English: Once daily dosing with 150 mg produced trough and mean 24 hour responses similar to twice daily dosing on the same total dose.
Croatian: Jednokratno dnevno doziranje od 150 mg tijekom 24 sata pokazuje najniži i prosječni terapijski odgovor sličan doziranju iste ukupne doze dva puta na dan.
English: At very high doses (≥ 500 mg/kg/day) degenerative changes in the kidney (such as interstitial nephritis, tubular distension, basophilic tubules, increased plasma concentrations of urea and creatinine) were induced by irbesartan in the rat and the macaque and are considered secondary to the hypotensive effects of the medicinal product which led to decreased renal perfusion.
Croatian: Pri vrlo visokim dozama (≥ 500 mg/kg/dan) irbesartan je izazvao degenerativne promjene na bubrezima (poput intersticijskog nefritisa, tubularne distenzije, bazofilnih tubula, povećane koncentracije ureje i kreatinina u plazmi) u štakora i makaki majmuna, što se smatra posljedicom hipotenzivnih učinaka lijeka koji dovode do smanjenja perfuzije bubrega.
English: The study examined the long-term effects (2 years) of Aprovel on the progression to clinical (overt) proteinuria (urinary albumin excretion rate (UAER) > 300 mg/day, and an increase in UAER of at least 30% from baseline).
Croatian: U ispitivanju su ispitivani dugotrajni učinci (2 godine) lijeka Aprovel na progresiju klinički izražene proteinurije (brzina izlučivanja albumina u mokraću > 300 mg/dan i porast u vrijednostima brzine izlučivanja albumina u mokraću od najmanje 30% u odnosu na početne vrijednosti).
English: In 1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/day and serum creatinine ranging from 1.0-3.0 mg/dl, the long-term effects (mean 2.6 years) of Aprovel on the progression of renal disease and all-cause mortality were examined.
Croatian: U 1715 hipertenzivnih bolesnika sa šećernom bolešću tipa 2, proteinurijom ≥ 900 mg/dan i serumskim kreatininom u rasponu od 1,0 do 3,0 mg/dl ispitivan je dugotrajan učinak lijeka Aprovel (prosječno 2,6 godina) na progresiju bubrežne bolesti i svih uzroka mortaliteta.
English: In patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan are not significantly altered.
Croatian: U bolesnika s oštećenom bubrežnom funkcijom ili u bolesnika na hemodijalizi, farmakokinetički parametri irbesartana nisu bitno promijenjeni.
English: The total body and renal clearance are 157176 and 3-3.5 ml/min, respectively.
Croatian: Ukupni tjelesni klirens iznosi 157-176 ml/min, a bubrežni klirens 3-3,5 ml/min.
English: For therapeutic doses of irbesartan in humans, the hyperplasia/ hypertrophy of the renal juxtaglomerular cells does not appear to have any relevance.
Croatian: Nije izgledno da je, pri terapijskim dozama irbesartana u ljudi, hiperplazija/hipertrofija bubrežnih jukstaglomerularnih stanica od bilo kakve važnosti.
English: Over a subsequent two week period where patients were re-randomized to either active medicinal product or placebo, patients on placebo had increases of 2.4 and 2.0 mmHg in SeSBP and SeDBP compared to +0.1 and -0.3 mmHg changes respectively in those on all doses of irbesartan (see section 4.2).
Croatian: Tijekom sljedeća dva tjedna kada su bolesnici ponovo randomizirani ili na lijek ili na placebo, bolesnici na placebu imali su porast od 2,4 i 2,0 mmHg za SjSKT i SjDKT, u usporedbi s promjenom od +0,1 i -0,3 mmHg u bolesnika na svim dozama irbesartana (vidjeti dio 4.2).
English: impaired renal function including cases of renal failure in patients at risk (see section 4.4)
Croatian: oštećena funkcija bubrega, uključujući slučajeve zatajenja bubrega u rizičnoj skupini bolesnika (vidjeti dio 4.4.).
English: The pharmacokinetic of digoxin was not altered by coadministration of irbesartan.
Croatian: Farmakokinetika digoksina nije se promijenila kod istodobne primjene irbesartana.
English: Limited accumulation of irbesartan (< 20%) is observed in plasma upon repeated once-daily dosing.
Croatian: Ograničeno nakupljanje irbesartana (< 20%) zabilježeno je u plazmi nakon primjene opetovanih doza jedanput na dan.
English: Aprovel slows the decrease of kidney function in patients with high blood pressure and type 2 diabetes.
Croatian: Aprovel usporava slabljenje bubrežne funkcije u bolesnika koji imaju povišen krvni tlak i boluju od šećerne bolesti tipa 2.
English: 14 - 28 - 56 - 84 - 98 tablets: Mon
Croatian: 14 - 28 - 56 - 84 - 98 tableta: PON
English: The blood pressure lowering effects of irbesartan and thiazide-type diuretics are additive.
Croatian: Učinci irbesartana i tiazidskih diuretika na snižavanje krvnog tlaka su aditivni.
English: In patients not adequately controlled by irbesartan alone, the addition of a low dose of hydrochlorothiazide (12.5 mg) to irbesartan once daily results in a further placebo-adjusted blood pressure reduction at trough of 7-10/3-6 mm Hg (systolic/diastolic).
Croatian: U bolesnika u kojih irbesartan u monoterapiji nedostatno kontrolira krvni tlak dodavanje male doze hidroklorotiazida (12,5 mg) jedanput na dan za ishod ima dodatno snižavanje krvnog tlaka, korigirano za placebo, u vrijeme najniže koncentracije u krvi od 7-10/3-6 mmHg (sistolički/dijastolički).
English: Reduction of blood pressure with 0.5 mg/kg (low), 1.5 mg/kg (medium) and 4.5 mg/kg (high) target titrated doses of irbesartan was evaluated in 318 hypertensive or at risk (diabetic, family history of hypertension) children and adolescents aged 6 to 16 years over a three week period.
Croatian: Smanjenje krvnog tlaka ispitivano je tijekom tri tjedna pri primjeni ciljanih titriranih doza od 0,5 mg/kg (niska doza), 1,5 mg/kg (srednja doza) i 4,5 mg/kg (visoka doza) irbesartana u 318 djece i adolescenata s hipertenzijom ili rizikom od hipertenzije (šećerna bolest, hipertenzija u povijesti bolesti obitelji) u dobi od 6 do 16 godina.
English: In diabetic hypertensive patients with microalbuminuria and normal renal function, hyperkalaemia (≥ 5.5 mEq/L) occurred in 29.4% of the patients in the irbesartan 300 mg group and 22% of the patients in the placebo group.
Croatian: U bolesnika sa šećernom bolešću i hipertenzijom, mikroalbuminurijom i normalnom bubrežnom funkcijom, hiperkalijemija (≥ 5,5 mEq/L) se razvila u 29,4% bolesnika koji su primali 300 mg irbesartana i u 22% bolesnika u placebo skupini.
English: Adverse reactions additionally reported from post-marketing experience are also listed.
Croatian: Također su navedene dodatne nuspojave koje su prijavljene nakon stavljanja lijeka u promet, a proizlaze iz spontanog prijavljivanja.
English: There is no clinical experience in patients with severe hepatic impairment.
Croatian: Nema kliničkog iskustva u bolesnika s teškim oštećenjem funkcije jetre.
English: SANOFI WINTHROP INDUSTRIE 30-36 Avenue Gustave Eiffel, BP 7166 F-37071 Tours Cedex 2 - France
Croatian: SANOFI WINTHROP INDUSTRIE 30-36 Avenue Gustave Eiffel, BP 7166 F-37071 Tours Cedex 2 - Francuska